A new report suggests that Johnson & Johnson’s profit-churning blood thinner Xarelto may be linked to eye hemorrhaging. Xarelto lawsuits have already been filed across the country by people who have experienced uncontrollable bleeding while taking the drug. Unlike warfarin, Xarelto has no antidote once bleeding incidents occur.
Older Patients at Risk for Eye Hemorrhaging When Switching From Warfarin to Xarelto
A new report in the June 2015 issue of JAMA Ophthalmology disclosed that patients who transitioned from warfarin to Xarelto experienced bleeding in the space between the eye’s lens and retina. The “vitreous hemorrhage” reportedly took place soon after the switch to Xarelto and then resolved on its own.
The authors of the report, Drs. John C. Hwang and Judy H. Hun, conducted clinical and angiographic tests after the bleeding events, which assessments did not reveal any abnormality in the eye that would explain the hemorrhage.
Drs. Hwang and Hun noted that all three patients in which they observed the Xarelto bleeding incidents were in their 70s and 80s. At the 2015 Annual Scientific Meeting of the American Geriatrics Society, it was reported that 74.1 percent of Xarelto bleeding events affect people who are 75 years of age or older.
The authors of the recent JAMA Ophthalmology report urge clinicians to be aware of the possibility of eye bleeding if they choose to switch their patients from warfarin to Xarelto.
Contact Waters Kraus & Paul to Learn More About Filing a Xarelto Lawsuit
If you have suffered injuries or the death of a loved one associated with Xarelto,contact us by email or call our attorneys at 800.226.9880 to learn more about how we can assist you with a Xarelto lawsuit.